As biosimilars continue to reshape the market, plan sponsors are looking for real savings – without added complexity. ProAct’s new BioPathways™ Program delivers targeted, clinically-aligned utilization management…
On April 23, 2026, the FDA granted accelerated approval to Otarmeni™ (lunsotogene parvec‑cwha) from Regeneron Pharmaceuticals – the first FDA‑approved gene therapy for patients with…
Gene therapy is an emerging class of treatment that targets disease at its source by repairing or replacing a faulty gene. Unlike traditional drugs that require ongoing use, many gene therapies…
Foundayo™ (orforglipron), Eli Lilly’s once‑daily oral GLP‑1 receptor agonist, was FDA‑approved on April 1, 2026 for chronic weight management in adults with obesity or overweight plus at least one weight‑related comorbidity…
Specialty pharmacy plays a critical role in caring for patients with complex, chronic conditions – and employers recognize its value. 98% of employers say specialty pharmacy…
